Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07416994, led by MediLink Therapeutics (Suzhou), and recruiting on the registry. Official title: A Multicenter, Randomised, Open-label, Phase III Study to Compare the Efficacy and Safety of YL202 and Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer. Planned enrolment is 440 participants (estimated). The study started in 2026-03-18 and primary completion is expected in 2028-08-31. No results have been posted on ClinicalTrials.gov.